Thrombosis research
-
Thrombosis research · Nov 1999
Randomized Controlled Trial Multicenter Study Clinical TrialThromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
Venous thromboembolism remains an important cause of maternal mortality. For women at risk during pregnancy, the recommended venous thromboembolismprophylaxis is unfractionated heparin. ⋯ Recurrence of venous thromboembolism and safety of treatments were assessed. Dalteparin administered once daily was safe and effective in thromboprophylaxis during pregnancy and postpartum.